The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication – Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favorable outcomes recently. New targets have been validated in this process where kinases lead the way. Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for the Relapsed and Refractory Multiple Myeloma (RRMM) and their successful commercial launch validate the strategy deployed by the companies. We expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML). Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium. The successful IPOs’ of Ambit and Onconova are indicators of the optimism prevailing amongst the investors, Patients and Physicians community.

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report.

Key Points Discussed in the Report
• Overview of the disease and Unmet need
• Drugs in the pipeline - Mechanism of Action (MoA) and Clinical Stage of development
- MDS - Lower-Risk, Higher-Risk and recurrent/ refractory MDS
- AML - Untreated/ newly diagnosed and Relapsed or Refractory AML
• Key milestones
• Launch Timeline and Commercial Opportunity of Late-stage pipeline (RR MDS and RR AML)
• M&A and Licensind deals in the last 5 years
• In-licensing and/or M&A Opportunity
• Detailed Company analysis: Includes Clinical data of drugs, Milestones, and Valuation
1. Ambit Biosciences (AMBI)
2. Onconova Therapeutics (ONTX)

Table Of Contents

Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
1. Executive Summary

2. Investment Drivers of The Select Companies Covered

3. Myelodysplastic syndrome (MDS)
3.1 Disease Overview
3.2 Unmet Need
3.3 Current Standard of Care
3.3.1 Supportive Care
3.3.2 Low-Intensity Therapy
3.3.3 High-Intensity Therapy
3.3.4 Recurrent/ Refractory or relapsed MDS

4. Acute Myelogenous Leukemia (AML)
4.1 Disease Overview
4.2 Current Standard of Care
4.2.1 AML pts younger than 60 years
a Induction Therapy
b Post-remission/ consolidation therapy
4.2.2 AML pts Older than 60 years
a Current treatment options - Hypomethylating agents and SCT
4.3 Unmet Need
4.4 Refractory or relapsed AML

5. Competitive Landscape: RR/ High-Risk MDS and RR AML

6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML

7. Key Milestones

8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML)

9. Drivers of MandA / Licensing Deals in MDS/ AML
9.1 Select MandA Deals in Last 5 Years - 2007 to 2012
9.2 Select Licensing Deals in Last 5 Years - 2007 to 2012
9.3 MandA and Licensing Deals Opportunity

10. Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)
10.1 Ambit Biosciences (AMBI)
10.1.1 Investment Drivers
10.1.2 Other Assets - Not Fully valued in the Price
10.1.3 Key Milestones
10.1.4 NPV Valuation - Scenario Analysis (Early Approval)
10.1.5 Background about AMBI's products
a. Quizaritinib - Key profile, Clinical Data, IP protection
b. Other assets - CEP-32496, AC410, and AC708
c. Competitive Landscape - Late- and Mid-stage AML drugs
d. Select JAK 2/1 Inhibitor: Late- and Mid-stage Pipeline
10.2 Onconova Therapeutics (ONTX)
10.2.1 Investment Drivers
10.2.2 Upside from Early-stage pipeline
10.2.3 Strong IP position
10.2.4 Key Milestones
10.2.5 NPV Valuation
10.2.6 Background about ONTX's products
a. Estybon (rigosertib) - Key Profile, Primary Indications
b. Rigosertib IV - 2nd-line Higher-Risk MDS (clinical data and
competition landscape)
c. Rigosertib Oral - 1st-line Lower-Risk MDS (clinical data and
competition landscape)
d. Estybon (rigosertib) - Label Expansions
• Metastatic Pancreatic cancer
• Head and Neck cancer
e. Other Early-stage drugs - ON 013105, Recilisib
f. Preclinical Programs - ON 1231320, ON 123300, ON 108600,
ON 044580
g. Patents
h. Collaboration/ Partnership Agreements



Companies Mentioned

Ambit Biosciences , Onconova Therapetuics, Celgene, Symbio

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with ...

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023 Summary Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered ...

Renal Cell Carcinoma: KOL Insight

Renal Cell Carcinoma: KOL Insight

  • $ 6 695
  • Industry report
  • February 2015
  • by Firstword Pharma

Will new checkpoint inhibitors revive immunotherapy in RCC? Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma ...


Download Unlimited Documents from Trusted Public Sources

Chemotherapy Market in the US

  • April 2015
    2 pages
  • Chemotherapy  

    Oncology  

    Cancer Therapy  

  • United States  

View report >

Nursing Home Industry in the US and Canada

  • April 2015
    17 pages
  • Nursing Home  

  • United States  

    Canada  

View report >

Therapy Industry in the UK

  • April 2015
    16 pages
  • Cancer  

  • United Kingdom  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.